PartnershipJul 22, 2026, 08:07 AM
Trinity Biotech Partners with Latch Medical for Biosensor-Guided Drug Delivery
AI Summary
Trinity Biotech plc announced a strategic collaboration with Latch Medical Limited to develop biosensor-guided precision drug delivery solutions. This partnership will integrate Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's Pharma Latch™ intradermal drug delivery technology to create next-generation metabolic health solutions for conditions like diabetes and obesity. As part of the collaboration, Trinity Biotech will also make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors.
Key Highlights
- Trinity Biotech announced a strategic collaboration with Latch Medical Limited.
- The partnership aims to develop biosensor-guided precision drug delivery solutions.
- It combines Trinity Biotech's AI-native CGM+ wearable biosensor platform.
- It also uses Latch Medical's Pharma Latch™ intradermal drug delivery technology.
- The collaboration focuses on next-generation metabolic health solutions for diabetes and obesity.
- Trinity Biotech will make a strategic equity investment in Latch Medical.
- Perceptive Advisors, Trinity Biotech's largest financial investor, supports the investment.
Price Impact
More from TRIB